Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Joern Henze

Showing results (1-10 of 4) with videos related to

Pageof 1
Sort By:
Hematology/Oncology Clinics of North America|October 8, 2013
LiposarcomasJoern Henze, Sebastian Bauer
Plos One|June 5, 2012
p53 modulation as a therapeutic strategy in gastrointestinal stromal tumorsJoern Henze, Thomas Mühlenberg, Susanne Simon, et al.
Scientific Reports|December 13, 2023
Evaluation of viscosities of typical drainage fluids to promote more evidence-based catheter size selectionErkan Celik, Lukas Goertz, Joern Henze, et al.
Nature Genetics|May 6, 2014
Dystrophin is a tumor suppressor in human cancers with myogenic programsYuexiang Wang, Adrian Marino-Enriquez, Richard R Bennett, et al.
Pageof 1

Showing results (1-10 of 4) with videos related to

Sort By:
Pageof 1
Hematology/Oncology Clinics of North America|October 8, 2013
LiposarcomasJoern Henze, Sebastian Bauer
Plos One|June 5, 2012
p53 modulation as a therapeutic strategy in gastrointestinal stromal tumorsJoern Henze, Thomas Mühlenberg, Susanne Simon, et al.
Scientific Reports|December 13, 2023
Evaluation of viscosities of typical drainage fluids to promote more evidence-based catheter size selectionErkan Celik, Lukas Goertz, Joern Henze, et al.
Nature Genetics|May 6, 2014
Dystrophin is a tumor suppressor in human cancers with myogenic programsYuexiang Wang, Adrian Marino-Enriquez, Richard R Bennett, et al.
Pageof 1